|
|
|
|
|
17.12.25 - 15:33
|
GSK Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für GSK mit einem Kursziel von 1700 Pence auf "Neutral" belassen. Die US-Zulassung für Exdensur als zusätzliche Medikation bei schwerem Asthma komme nicht überraschend, ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.12.25 - 10:54
|
GSK Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1600 Pence auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am Dienstag vorliegenden Auswertung wöchentlicher Verschreibungsdaten ......
|
|
|
|
|
16.12.25 - 07:42
|
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director (Business Wire)
|
|
|
OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that Gijs van den Brink, MD, PhD, has been appointed as an independent director to the company's Board of Directors. Dr. van den Brink is a highly accomplished researcher and drug developer, having led immunology research and clinical development at both Roche and GSK.
“Gijs brings an exceptional blend of scientific depth, clinical insight, and strategic leadership to our board of directors,” said Calluna CEO Mark Gaffney. “We are thrilled to welcome him and are confident his expertise will strengthen our mission as we advance our pipeline in fibrotic and other inflammatory disorders.”
Dr. van den Brink had a distinguished tenure at Roche, where he served on the Pharma Research and Early Development (pRED) leadership team and was SVP and Global Head of Immunology, CVM, Infectious Diseases, and Ophthalmol...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
